mGlu1 antagonist or negative mGlu1 allosteric modulator (NAM) would reinforce the paracrine effect of GABA at GABAB heteroreceptors located on glutamatergic nerve endings, positively tuning the excessive glutamate release that often characterize central neurological diseases. The gene discussed is GRM1; the disease is nervous system disorder.